Affiliation:
1. Department of Dermatology Venereology and Allergology University Hospital Frankfurt/Main Frankfurt/Main Germany
2. Merz Pharmaceuticals GmbH Frankfurt am Main Germany
3. formerly AbbVie Deutschland GmbH & Co. KG Wiesbaden Germany
Abstract
SummaryBackground and ObjectivesPsoriatic arthritis (PsA) warrants early diagnosis and treatment for optimal results. This study aimed to elucidate routine monitoring activities for PsA with concurrent psoriasis (PsO) by dermatologists to gather data on how conditions for optimal treatment are ensured.Patients and MethodsThis non‐interventional, prospective, epidemiological, cross‐sectional study (2016–2019) included patients with confirmed PsA from dermatologists. Descriptive statistics were conducted for center and patient characteristics as well as for data of PsA monitoring and treatment stratified by different center types.Results212 patients from 34 office‐based physicians, five non‐university hospitals, and nine university hospitals were included. The majority of the PsA patients were diagnosed by a rheumatologist (> 55% in each center type) at an early or intermediate stage (> 59%). Treatment was initiated most frequently by a dermatologist (office‐based physicians: 69.6%, hospitals: 60.9%, university hospitals: 82.9%). Patients were treated with biologics more frequently in university hospitals (single therapy: 43.9%, in combination with systemic therapy: 26.8%) compared to private practices (single: 44.6%, combination: 13.5%) and non‐university hospitals (single: 34.8%, combination: 8.7%).ConclusionsAs PsA diagnosis was performed most frequently by rheumatologists whereas treatment was primarily initiated by dermatologists, an optimal collaboration between these specialists is crucial.